Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.

Hatemi G., Mahr A., Takeno M., Kim D. Y., Saadoun D., DİRESKENELİ R. H., ...Daha Fazla

Clinical and experimental rheumatology, cilt.39, sa.5, 2021 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.55563/clinexprheumatol/ra8ize
  • Dergi Adı: Clinical and experimental rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Behcet's syndrome, long-term treatment, phosphodiesterase 4 inhibitor, quality of life, oral ulcers, PHOSPHODIESTERASE-4 INHIBITOR, PSORIATIC-ARTHRITIS
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Objective. This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behcet's syndrome (BS) up to 64 weeks.